Coronavirus COVID-19 IgM ELISA Assay Kit
Coronavirus COVID-19 IgM ELISA Assay Kit was developed and manufactured in the US
Size: 1×96 wells
Sensitivity: Cut-off control
Incubation Time: 1 Hour, 20 minutes
Sample Type: Serum
Species Sample: Human
Sample Size: 20 µL
Alternative Names: Serology, Coronavirus, COVID-19, Corona, Serological
RUO, CE-Marked
Controls Included
Cross Reactivity
Panels were studied with a minimum of five confirmed disease state samples with this serology assay. No interference was observed for the following disease or infectious agents:
- Anti-influenza A
- Anti-influenza B
- Hepatitis C (HCV)
- Antinuclear Antibodies (ANA)
- Respiratory Syncytial (RSV)
Assay Principle
The COVID-19 IgM ELISA Assay Kit is designed, developed, and produced for the qualitative measurement of the COVID-19 IgM antibody in serum samples. This COVID-19 serology ELISA assay utilizes the microplate based enzyme immunoassay technique.
Assay controls and samples, as well as the biotinylated COVID-19 specific peptide antigens are added to the microtiter wells of a microplate that was coated with a anti-human IgM specific antibody. After the first incubation period, the unbound protein matrix is removed with a subsequent washing step. A horseradish peroxidase (HRP) labeled streptavidin is added to each well. After an incubation period, an immunocomplex of ” Anti-hIgM antibody – human nCoV IgM antibody – HRP labeled COVID-19 antigen” is formed if there is novel coronavirus IgM antibody present in the tested materials. The unbound tracer antibody is removed by the subsequent washing step. HRP-labeled COVID-19 antigen tracer bound to the well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the tracer antibody bound to the coronoavirus IgM on the wall of the microtiter well is proportional to the amount of the coronavirus IgM antibody level in the tested material.
